title: Expression of bcl-2 and p53 in induction of esophageal cancer cell apoptosis by ECRG2 in combination with cisplatin.
abstract: OBJECTIVE
  To investigate the mechanisms of induction of apoptosis of esophageal cancer cells by esophageal cancer-related gene 2 (ECRG2) in combination with cisplatin (DDP).
  
  
  METHODS
  Hoechest staining was performed to analyze the effects of single ECRG2 and ECRG2 in combination with DDP on apoptosis of EC9706 cells. The expression levels of p53 and bcl-2 mRNA and protein were determined by RT-PCR and Western blotting, respectively.
  
  
  RESULTS
  The number of apoptotic cells after the treatment with ECRG2 in combination with DDP for 24 hours was more than that after the treatment with single ECRG2. RT-PCR and Western blotting showed that the expression levels of bcl-2 mRNA and protein were both down-regulated, while p53 mRNA and protein were both up-regulated in the cells treated with ECRG2 in combination with DDP compared with those given ECRG2 alone.
  
  
  CONCLUSIONS
  ECRG2 in combination with DDP can enhance the apoptosis of EC9706 cells, possibly by down-regulating bcl-2 expression and up-regulating p53.
authors.affiliation: College of Basic Medicine, Xinxiang Medical University; Key Laboratory for Medical Tissue Regeneration of Henan Province, Xinxiang, China E-mail : shy80825@163.com.
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Song
authors.forename: Xiao-Hui
authors.initials: XH
authors.lastname: Deng
authors.forename: Guo-Yan
authors.initials: GY
authors.lastname: Yuan
authors.forename: Xin-Fang
authors.initials: XF
authors.lastname: Hou
authors.forename: Zhen-Dong
authors.initials: ZD
authors.lastname: Zhu
authors.forename: Li
authors.initials: L
authors.lastname: Zhou
authors.forename: Ming-Xin
authors.initials: MX
authors.lastname: Ren
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D015536:Down-Regulation; D019008:Drug Resistance, Neoplasm; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D053491:Proteinase Inhibitory Proteins, Secretory / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis; D000074162:Serine Peptidase Inhibitors, Kazal Type; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis* / Q000235:genetics; D015854:Up-Regulation
chemical_list: D000970:Antineoplastic Agents; D053491:Proteinase Inhibitory Proteins, Secretory; D019253:Proto-Oncogene Proteins c-bcl-2; D012333:RNA, Messenger; C473799:SPINK7 protein, human; D000074162:Serine Peptidase Inhibitors, Kazal Type; D016159:Tumor Suppressor Protein p53; D002945:Cisplatin